Wanjia Group Holdings Limited completed its 1-for-1 Rights Issue after placing all 257.60 million unsubscribed shares at HK$0.08 per share—the same as the subscription price. Total valid acceptances reached 302.62 million shares, representing 54.02% of the 560.22 million offered, while the balance was fully placed with at least six independent investors.

Gross proceeds amounted to HK$44.82 million and net proceeds were approximately HK$40.82 million. The company intends to allocate 42.40% of the net proceeds (about HK$17.32 million) to expand its pharmaceutical wholesale, distribution, and hemodialysis services; 33.10% (about HK$13.50 million) to settle HK$5.00 million in trade and other payables and repay HK$8.50 million due to a director; and 24.50% (about HK$10.00 million) to general working capital.

Share capital doubled from 560.22 million to 1.12 billion shares. Post-issue, Power King (controlled by Ms. Yung) and connected parties maintained a 28.12% stake, while the new placees hold 22.99%. Public shareholders’ aggregate interest decreased from 71.91% to 48.89%.

The Rights Issue triggered adjustments to 80.79 million outstanding share options: • 26 Oct 2018 grant – exercise price reduced from HK$0.668 to HK$0.540; shares issuable increased from 13.02 million to 16.12 million. • 24 Apr 2020 grant – exercise price reduced from HK$0.190 to HK$0.153; shares issuable increased from 17.17 million to 21.26 million. • 5 Sep 2023 grant – exercise price reduced from HK$0.094 to HK$0.076; shares issuable increased from 50.60 million to 62.65 million.

Fully-paid Rights Share certificates will be posted on 1 April 2026, and trading in the new shares is scheduled to begin on 2 April 2026.